Weekly Research Analysts’ Ratings Changes for Mirum Pharmaceuticals (MIRM)

Several brokerages have updated their recommendations and price targets on shares of Mirum Pharmaceuticals (NASDAQ: MIRM) in the last few weeks:

• 8/16/2026 – Mirum Pharmaceuticals was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/8/2026 – Mirum Pharmaceuticals was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/6/2026 – Mirum Pharmaceuticals was upgraded by Weiss Ratings from “sell (d-)” to “sell (d)”.
• 8/6/2026 – Mirum Pharmaceuticals was given a new $123.00 price target by Robert W. Baird.
• 8/6/2026 – Mirum Pharmaceuticals was given a new $137.00 price target by Morgan Stanley.
• 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by Royal Bank Of Canada from $148.00 to $135.00. They now have an “outperform” rating on the stock.
• 8/6/2026 – Mirum Pharmaceuticals had its “outperform” rating reaffirmed by Citigroup Inc..
• 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by TD Cowen from $145.00 to $140.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by Citizens Jmp from $146.00 to $137.00. They now have a “market outperform” rating on the stock.
• 8/6/2026 – Mirum Pharmaceuticals had its price target lowered by HC Wainwright from $185.00 to $140.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Mirum Pharmaceuticals had its price target raised by Royal Bank Of Canada from $142.00 to $148.00. They now have an “outperform” rating on the stock.
• 7/2/2026 – Mirum Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $115.00 to $125.00. They now have an “overweight” rating on the stock.
• 6/23/2026 – Mirum Pharmaceuticals was downgraded by Weiss Ratings from “sell (d)” to “sell (d-)”.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 30,000 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $95.84, for a total transaction of $2,875,200.00. Following the transaction, the chief executive officer owned 194,309 shares of the company’s stock, valued at $18,622,574.56. This trade represents a 13.37% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Eric Bjerkholt sold 6,001 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $99.90, for a total value of $599,499.90. Following the completion of the transaction, the chief financial officer owned 36,355 shares of the company’s stock, valued at approximately $3,631,864.50. The trade was a 14.17% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 133,156 shares of company stock valued at $13,763,562 in the last quarter. Insiders own 8.32% of the company’s stock.

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.